Related Experiment Video

Updated: May 21, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Preclinical drug development for childhood cancer

Lucas Moreno1, Louis Chesler, Darren Hargrave

  • 1The Royal Marsden NHS Foundation Trust, Children and Young People's Unit, Sutton, Surrey, UK. Lucas.Moreno@icr.ac.uk

Expert Opinion on Drug Discovery
|June 1, 2012
PubMed
Abstract

Insights

Developing new anticancer drugs for children presents unique challenges. Advances in preclinical drug development and collaborative efforts are paving the way for more effective targeted therapies in paediatric oncology.

Area of Science:

  • Paediatric Oncology
  • Drug Development
  • Cancer Therapeutics

Background:

  • Childhood cancers require novel therapeutic strategies due to poor prognosis and unique developmental aspects.
  • Anticancer drug development for paediatric malignancies faces distinct challenges compared to adult cancers.

Purpose of the Study:

  • To review recent advances in preclinical drug development for paediatric malignancies.
  • To highlight strategies for overcoming challenges in childhood cancer drug development.
  • To illustrate biology-driven drug development in paediatric oncology.

Main Methods:

  • Review of current preclinical models and their limitations.
  • Analysis of the roles of academia, regulatory bodies, and industry.
  • Examination of established preclinical research networks and collaborations.

Main Results:

  • Enhanced understanding of preclinical models and their application in paediatric oncology.
  • Successful examples of targeted agents in childhood solid malignancies.
  • Strengthened collaborations among academia, industry, and regulators.

Conclusions:

  • Advanced preclinical models and testing platforms are crucial for efficient, biologically-driven drug development.
  • Targeted therapies show promise for malignancies like neuroblastoma, medulloblastoma, and high-grade glioma.
  • Improved preclinical strategies are essential to combat leading causes of childhood cancer mortality.

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...